{"id":"ret","name":"RET","symbol":"RET","route":"/targets/ret/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165731","uniprot":"https://www.uniprot.org/uniprotkb/P07949/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P07949","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2041","open-targets":"https://platform.opentargets.org/target/ENSG00000165731","civic":"https://civicdb.org/genes/5979/summary","oncokb":"https://www.oncokb.org/gene/RET","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RET","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=RET","depmap":"https://depmap.org/portal/gene/RET?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000165731-RET","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5979","omim":"https://www.omim.org/entry/164761"}],"products":[{"id":"al2846","name":"AL2846","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/al2846/"},{"id":"cabozantinib","name":"Cabozantinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)","route":"/drugs/cabozantinib/"},{"id":"ep0031","name":"EP0031","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/ep0031/"},{"id":"guardant360-cdx","name":"Guardant360 CDx","status":"approved","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","route":"/drugs/guardant360-cdx/"},{"id":"lenvatinib","name":"Lenvatinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)","route":"/drugs/lenvatinib/"},{"id":"oncomine-dx-target-test","name":"Oncomine Dx Target Test","status":"approved","modality":"Tissue NGS companion diagnostic test (multi-gene panel)","route":"/drugs/oncomine-dx-target-test/"},{"id":"pralsetinib","name":"Pralsetinib","status":"approved","modality":"Small-molecule kinase inhibitor (RET)","route":"/drugs/pralsetinib/"},{"id":"regorafenib","name":"Regorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor","route":"/drugs/regorafenib/"},{"id":"selpercatinib","name":"Selpercatinib","status":"approved","modality":"Small-molecule kinase inhibitor (RET)","route":"/drugs/selpercatinib/"},{"id":"vandetanib","name":"Vandetanib","status":"approved","modality":"Small-molecule kinase inhibitor (RET, VEGFR, EGFR)","route":"/drugs/vandetanib/"}],"trials":[{"id":"nct04194775","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","nct":"NCT04194775","phase":"3","status":"active"},{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"nct03829462","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","nct":"NCT03829462","phase":"3","status":"active"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct03755791","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","nct":"NCT03755791","phase":"3","status":"active"},{"id":"cabinet","name":"CABINET (Alliance A021602)","nct":"NCT03375320","phase":"3","status":"positive"},{"id":"leap-012","name":"LEAP-012","nct":"NCT04246177","phase":"3","status":"mixed"},{"id":"nct03690388","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","nct":"NCT03690388","phase":"3","status":"active"},{"id":"contact-03","name":"CONTACT-03","nct":"NCT04338269","phase":"3","status":"negative"},{"id":"libretto-431","name":"LIBRETTO-431","nct":"NCT04194944","phase":"3","status":"positive"},{"id":"libretto-531","name":"LIBRETTO-531","nct":"NCT04211337","phase":"3","status":"positive"},{"id":"cosmic-313","name":"COSMIC-313","nct":"NCT03937219","phase":"3","status":"mixed"},{"id":"leap-002","name":"LEAP-002","nct":"NCT03713593","phase":"3","status":"negative"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"keynote-775","name":"KEYNOTE-775 / Study 309","nct":"NCT03517449","phase":"3","status":"positive"},{"id":"checkmate-9er","name":"CheckMate 9ER","nct":"NCT03141177","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"celestial","name":"CELESTIAL","nct":"NCT01908426","phase":"3","status":"positive"},{"id":"reflect","name":"REFLECT","nct":"NCT01761266","phase":"3","status":"positive"},{"id":"resorce","name":"RESORCE","nct":"NCT01774344","phase":"3","status":"positive"},{"id":"comet-1","name":"COMET-1","nct":"NCT01605227","phase":"3","status":"negative"},{"id":"concur","name":"CONCUR","nct":"NCT01584830","phase":"3","status":"positive"},{"id":"select-lenvatinib","name":"SELECT","nct":"NCT01321554","phase":"3","status":"positive"},{"id":"correct","name":"CORRECT","nct":"NCT01103323","phase":"3","status":"positive"},{"id":"grid","name":"GRID","nct":"NCT01271712","phase":"3","status":"positive"},{"id":"exam","name":"EXAM","nct":"NCT00704730","phase":"3","status":"positive"},{"id":"zeta","name":"ZETA","nct":"NCT00410761","phase":"3","status":"positive"},{"id":"nct07730489","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","nct":"NCT07730489","phase":"3","status":"planned"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct06860971","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","nct":"NCT06860971","phase":"3","status":"recruiting"},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","nct":"NCT03729245","phase":"3"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"nct04819100","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT04819100","phase":"3","status":"active"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct06199973","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","nct":"NCT06199973","phase":"3","status":"active"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"nct05794971","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","nct":"NCT05794971","phase":"3","status":"recruiting"},{"id":"nct07011719","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","nct":"NCT07011719","phase":"3","status":"recruiting"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"nct07134205","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","nct":"NCT07134205","phase":"3","status":"planned"},{"id":"nct05462613","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","nct":"NCT05462613","phase":"2/3","status":"recruiting"},{"id":"gbm-agile","name":"GBM AGILE","nct":"NCT03970447","phase":"platform","status":"recruiting"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"nct04280081","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","nct":"NCT04280081","phase":"2","status":"active"},{"id":"papmet","name":"PAPMET (SWOG S1500)","nct":"NCT02761057","phase":"2","status":"positive"},{"id":"cabone","name":"CABONE","nct":"NCT02243605","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"regobone","name":"REGOBONE","nct":"NCT02389244","phase":"2","status":"positive"},{"id":"nct06829355","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","nct":"NCT06829355","phase":"2","status":"recruiting"},{"id":"nct06887218","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","nct":"NCT06887218","phase":"2","status":"recruiting"},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","nct":"NCT07679399","phase":"2","status":"recruiting"},{"id":"nct07099794","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","nct":"NCT07099794","phase":"2","status":"planned"},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","nct":"NCT06962787","phase":"2","status":"recruiting"},{"id":"nct05859217","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","nct":"NCT05859217","phase":"2","status":"planned"},{"id":"nct06246643","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","nct":"NCT06246643","phase":"2","status":"active"},{"id":"nct06147570","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","nct":"NCT06147570","phase":"2","status":"recruiting"},{"id":"nct04302025","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","nct":"NCT04302025","phase":"2","status":"recruiting"},{"id":"nct03634540","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","nct":"NCT03634540","phase":"2","status":"active"},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","nct":"NCT07282262","phase":"2","status":"recruiting"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct01639508","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","nct":"NCT01639508","phase":"2","status":"recruiting"},{"id":"nct07829874","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","nct":"NCT07829874","phase":"2","status":"planned"},{"id":"nct05057052","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","nct":"NCT05057052","phase":"2","status":"recruiting"},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","nct":"NCT07159217","phase":"2","status":"planned"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct06949982","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","nct":"NCT06949982","phase":"2","status":"recruiting"},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","nct":"NCT06028633","phase":"2","status":"planned"},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","nct":"NCT06963060","phase":"2","status":"recruiting"},{"id":"nct06558773","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","nct":"NCT06558773","phase":"2","status":"recruiting"},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","nct":"NCT06389500","phase":"2","status":"planned"},{"id":"nct06849492","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","nct":"NCT06849492","phase":"2","status":"planned"},{"id":"nct07263360","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT07263360","phase":"2","status":"planned"},{"id":"nct05985109","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","nct":"NCT05985109","phase":"2","status":"recruiting"},{"id":"nct05170438","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","nct":"NCT05170438","phase":"2","status":"active"},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","nct":"NCT06919848","phase":"2","status":"planned"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct05903833","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","nct":"NCT05903833","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","nct":"NCT06230471","phase":"2","status":"recruiting"},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT06852287","phase":"2","status":"recruiting"},{"id":"nct07530445","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","nct":"NCT07530445","phase":"2","status":"recruiting"},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","nct":"NCT07670273","phase":"2","status":"recruiting"},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","nct":"NCT07704177","phase":"2","status":"recruiting"},{"id":"nct07310173","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","nct":"NCT07310173","phase":"2","status":"recruiting"},{"id":"nct06892925","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","nct":"NCT06892925","phase":"2","status":"active"},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","nct":"NCT07110064","phase":"2","status":"recruiting"},{"id":"nct06911684","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","nct":"NCT06911684","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct05963490","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT05963490","phase":"2","status":"recruiting"},{"id":"nct06425133","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","nct":"NCT06425133","phase":"2","status":"recruiting"},{"id":"nct07213570","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","nct":"NCT07213570","phase":"2","status":"recruiting"},{"id":"nct05112991","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","nct":"NCT05112991","phase":"2","status":"recruiting"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct05822752","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","nct":"NCT05822752","phase":"2","status":"active"},{"id":"nct04701476","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","nct":"NCT04701476","phase":"2","status":"recruiting"},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","nct":"NCT04875585","phase":"2","status":"recruiting"},{"id":"nct07219459","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","nct":"NCT07219459","phase":"2","status":"recruiting"},{"id":"nct03899792","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","nct":"NCT03899792","phase":"1/2","status":"active"},{"id":"nct03157128","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","nct":"NCT03157128","phase":"1/2","status":"active"},{"id":"arrow-thyroid","name":"ARROW (thyroid cohorts)","nct":"NCT03037385","phase":"1/2","status":"positive"},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","nct":"NCT06682780","phase":"1/2","status":"recruiting"},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","nct":"NCT07040228","phase":"1/2","status":"recruiting"},{"id":"nct07750041","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07750041","phase":"1/2","status":"planned"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct04008797","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","nct":"NCT04008797","phase":"1/2","status":"active"},{"id":"nct05443126","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","nct":"NCT05443126","phase":"1/2","status":"recruiting"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","nct":"NCT04300556","phase":"1/2","status":"recruiting"},{"id":"nct07293351","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","nct":"NCT07293351","phase":"1/2","status":"recruiting"},{"id":"nct03539822","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","nct":"NCT03539822","phase":"1/2","status":"recruiting"},{"id":"nct04977453","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","nct":"NCT04977453","phase":"1/2","status":"recruiting"},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","nct":"NCT07636798","phase":"1/2","status":"recruiting"},{"id":"nct05024214","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","nct":"NCT05024214","phase":"1/2","status":"recruiting"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct06140576","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","nct":"NCT06140576","phase":"1/2","status":"planned"},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","nct":"NCT04781192","phase":"1/2","status":"active"}],"pathways":["nsclc-signalling","thyroid-cancer-signalling"],"companies":["bayer","blueprint-medicines","eisai","eli-lilly","ellipses-pharma","exelixis","guardant-health","imagene-ai","ipsen","lucence","merck","rigel-pharmaceuticals","sanofi","sino-biopharm","thermo-fisher"],"keyPapers":["paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-lindeman-lung-molecular-testing-guideline-jto-2018","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017"],"hotspots":[{"label":"M918T","position":918,"kind":"activating","drugs":["selpercatinib","pralsetinib","vandetanib","cabozantinib"]},{"label":"C634R and other cysteine codons","position":634,"kind":"activating","drugs":["selpercatinib","pralsetinib"]},{"label":"V804M / V804L (gatekeeper)","position":804,"kind":"resistance","drugs":["selpercatinib","pralsetinib"]},{"label":"G810R/S/C (solvent front)","position":810,"kind":"resistance","drugs":[]}],"openQuestions":[],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"foundationone-liquid-cdx","name":"FoundationOne Liquid CDx","cutoff":"Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue"},{"id":"oncomine-dx","name":"Oncomine Dx Target Test","cutoff":"Per companion claim: BRAF V600E (dabrafenib plus trametinib), ROS1 fusions (crizotinib), EGFR (gefitinib), RET fusions (pralsetinib), MET exon 14 (tepotinib), EGFR exon 20 insertions"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}